Show simple item record

Clinical implications of hyperprogression with immune checkpoint inhibitors in patients with head and neck squamous cell carcinoma (HNSCC)

dc.contributor.authorEconomopoulou, P
dc.contributor.authorSpathas, NS
dc.contributor.authorPapaxoinis, Georgios
dc.contributor.authorAnastasiou, M
dc.contributor.authorGkotzamanidou, M
dc.contributor.authorKotsantis, I
dc.contributor.authorGavrielatou, N
dc.contributor.authorOikonomopoulos, N
dc.contributor.authorKirodimos, E
dc.contributor.authorVagia, EM
dc.contributor.authorKavourakis, G
dc.contributor.authorPsyrri, A
dc.date.accessioned2019-11-19T16:01:04Z
dc.date.available2019-11-19T16:01:04Z
dc.date.issued2019en
dc.identifier.citationEconomopoulou P, Spathas NS, Papaxoinis G, Anastasiou M, Gkotzamanidou M, Kotsantis I, et al. Clinical implications of hyperprogression with immune checkpoint inhibitors in patients with head and neck squamous cell carcinoma (HNSCC). J Clin Oncol. 2019;37(15_suppl):6034-.en
dc.identifier.doi10.1200/JCO.2019.37.15_suppl.6034en
dc.identifier.urihttp://hdl.handle.net/10541/622442
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/JCO.2019.37.15_suppl.6034en
dc.titleClinical implications of hyperprogression with immune checkpoint inhibitors in patients with head and neck squamous cell carcinoma (HNSCC)en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentAttikon University Hospital, Athens, Greeceen
dc.identifier.journalJournal of Clinical Oncologyen


This item appears in the following Collection(s)

Show simple item record